Results 171 to 180 of about 2,929 (206)

Vonoprazan

Reactions Weekly, 2022
openaire   +2 more sources

Vonoprazan

Reactions Weekly, 2020
openaire   +2 more sources

Vonoprazan

Reactions Weekly, 2018
openaire   +2 more sources

Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial

Gastroenterology, 2022
Francis Mégraud, Colin W Howden
exaly  

Vonoprazan

Reactions Weekly, 2019
openaire   +2 more sources

Vonoprazan (Voquezna) for Nonerosive GERD

The Medical Letter on Drugs and Therapeutics
The potassium-competitive acid blocker vonoprazan (Voquezna – Phathom), which was approved earlier for treatment of erosive esophagitis, has now been approved by the FDA for relief of heartburn associated with nonerosive gastroesophageal reflux disease (GERD) in adults.1 Vonoprazan is also available copackaged with amoxicillin (Voquezna Dual Pak) and ...
openaire   +2 more sources

Vonoprazan-associated nephrotoxicity: extensive real-world evidence from spontaneous adverse drug reaction reports

Kidney International, 2022
Masami Tsuchiya, Hirotoshi Iihara, Daichi Watanabe   +2 more
exaly  

Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial

Gastroenterology, 2023
Loren Laine
exaly  

Lansoprazole/vonoprazan

Reactions Weekly, 2021
openaire   +1 more source

The Effect of Food on the Pharmacokinetics of the Potassium‐Competitive Acid Blocker Vonoprazan

Clinical Pharmacology in Drug Development, 2022
Colin W Howden
exaly